A Comparison of Sustained-release Bupropion and Placebo for Smokeless Tobacco Cessation
Abstract:Objective: To evaluate the potential efficacy of bupropion sustained release when used in combination with minimal counseling for moist snuff cessation in males. Methods: A double-blind, placebo-controlled 3-month trial. The active treatment group (n=35) received bupropion SR at 150 mg/qd day for the first 3 days, then beginning day 4 through day 49 (7 weeks) 150 mg/ b.i.d. The placebo group (n=35) received 1 tablet qd for 3 days and beginning day 4 through day 49, 1 tablet/b.i.d. Results: Bupropion 300 mg/day (150 b.i.d.) produced significantly higher quit rates for smokeless tobacco cessation at the end of treatment (7 weeks) than placebo (p=0.04) with an OR of 2.73. Conclusion: Bupropion SR appears to be effective for smokeless tobacco cessation.
Document Type: Research Article
Affiliations: 1: Addiction and Psychiatric Medicine Research, Department of Behavioral Medicine & Psychiatry, West Virginia University School of Medicine, Morgantown, WV. 2: Department of Community Medicine, West Virginia University School of Medicine, Morgantown, WV.
Publication date: September 1, 2002
The American Journal of Health Behavior seeks to improve the quality of life through multidisciplinary health efforts in fostering a better understanding of the multidimensional nature of both individuals and social systems as they relate to health behaviors.
The Journal aims to provide a comprehensive understanding of the impact of personal attributes, personality characteristics, behavior patterns, social structure, and processes on health maintenance, health restoration, and health improvement; to disseminate knowledge of holistic, multidisciplinary approaches to designing and implementing effective health programs; and to showcase health behavior analysis skills that have been proven to affect health improvement and recovery.
- Editorial Board
- Information for Authors
- Submit a Paper
- Subscribe to this Title
- Review Board
- Reprints and Permissions
- ingentaconnect is not responsible for the content or availability of external websites